NeoStem is developing an immunotherapeutic applicable across multiple solid tumors with Special Protocol Assessment, Fast Track and Orphan Drug designations for a Phase 3 program in metastatic melanoma and near-term development milestones.
Enhancingthe body’s healing response
Rebalancingthe immune system
Innovatingdevelopment and manufacturing of cell-based therapies
NeoStem’s subsidiary, PCT, provides development manufacturing capabilities to the cell therapy industry while supporting the development of NeoStem’s proprietary cell therapy products.
NeoStem’s Investigational Targeted Cancer Immunotherapy For Late Stage Melanoma (2 minute)
See how NeoStem's Phase III investigational targeted cancer immunotherapy, NBS20 (eltrapuldencel-T), is created and administered. The product candidate is being evaluated for the treatment of patients suffering from late stage malignant melanoma.
News + EventsNeoStem's Lead Immuno-Oncology Product Candidate, NBS20, Receives ATMP Classification from European Medicines Agency April 27, 2015 - Learn MoreNeoStem Announces Expanded Cell Therapy Manufacturing Relationship with Kite Pharma April 20, 2015 - Learn MoreNeoStem Announces Extension of Study Under Grant from California Institute of Regenerative Medicine (CIRM) to Fund Research of Retinal Disease April 9, 2015 - Learn More
Dear NeoStem Shareholders, As you might imagine, the first two months of my tenure as the Chief Executive O.... Read More
After an extensive search, it is with great pleasure that I have the opportunity today to introduce Dr. Dav.... Read More